{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:24:12Z","timestamp":1773213852796,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,23]],"date-time":"2015-09-23T00:00:00Z","timestamp":1442966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Daiichi Sankyo Europe GmbH, Munich, Germany"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2016,6]]},"abstract":"This post hoc analysis from the Sevikar Compared to the Combination of Perindopril Plus Amlodipine on Central Arterial Blood Pressure in Patients With Moderate\u2010to\u2010Severe Hypertension (SEVITENSION) study assessed the efficacy and tolerability of olmesartan (OLM<\/jats:styled-content>) and amlodipine (AML<\/jats:styled-content>) in reducing central systolic blood pressure (CSBP<\/jats:styled-content>) compared with perindopril (PER<\/jats:styled-content>) plus AML<\/jats:styled-content> in hypertensive patients with type 2 diabetes. Patients were randomized to OLM<\/jats:styled-content>\/AML<\/jats:styled-content> 40\/10 mg or PER<\/jats:styled-content>\/AML<\/jats:styled-content> 8\/10 mg for 24 weeks. The primary efficacy endpoint was the absolute change in CSBP<\/jats:styled-content> from baseline to week 24, which was greater with OLM<\/jats:styled-content>\/AML<\/jats:styled-content> (\u221213.72\u00b11.14 mm Hg) compared with PER<\/jats:styled-content>\/AML<\/jats:styled-content> (\u221210.21\u00b11.11 mm Hg). The between\u2010group difference was \u22123.51\u00b11.60 mm Hg (95% confidence interval, \u22126.66 to \u22120.36 mm Hg) and was within the noninferiority margin (2 mm Hg) as well as the superiority margin (0 mm Hg). In addition, OLM<\/jats:styled-content>\/AML<\/jats:styled-content> was associated with a higher proportion of patients achieving blood pressure normalization. In hypertensive patients with diabetes, the fixed\u2010dose combination of OLM<\/jats:styled-content>\/AML<\/jats:styled-content> was superior to PER<\/jats:styled-content>\/AML<\/jats:styled-content> in reducing CSBP<\/jats:styled-content>, as well as other secondary endpoints.<\/jats:p>","DOI":"10.1111\/jch.12673","type":"journal-article","created":{"date-parts":[[2015,9,23]],"date-time":"2015-09-23T13:01:45Z","timestamp":1443013305000},"page":"528-535","source":"Crossref","is-referenced-by-count":9,"title":["Fixed\u2010Combination Olmesartan\/Amlodipine Was Superior to Perindopril + Amlodipine in Reducing Central Systolic Blood Pressure in Hypertensive Patients With Diabetes"],"prefix":"10.1111","volume":"18","author":[{"given":"Luis M.","family":"Ruilope","sequence":"first","affiliation":[{"name":"Institute of Research & Hypertension Unit Hospital 12 de Octubre Madrid Spain"},{"name":"Department of Public Health and Preventive Medicine Universidad Autonomy Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the SEVITENSION Study Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,9,23]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.03.031"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.107.089078"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2013.23"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283220ea4"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.595496"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801317"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0076-6"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2008.00012.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.162446"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.00612"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(89)90113-6"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-005-0177-z"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2011.01.011"},{"key":"e_1_2_9_15_1","first-page":"522","article-title":"The control of hypertension in persons with diabetes: a public health approach","volume":"102","author":"Bild D","year":"1987","journal-title":"Public Health Rep"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.37.4.1053"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-14-148"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61303-8"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.12.1410"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3281fc975a"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2011.04.011"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328333146d"},{"key":"e_1_2_9_23_1","unstructured":"Committee for Proprietary Medicinal Products (CPMP).Points to consider on switching between superiority and non\u2010inferiority (CPMP\/EWP\/482\/99). 2000:European Agency for the Evaluation of Medicinal Products.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003658.pdf. Accessed September 4 2015."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000431740.32696.cc"},{"key":"e_1_2_9_25_1","unstructured":"Actavis UK Ltd.Summary of product characteristics: perindopril 8mg tablets.2014;http:\/\/www.medicines.org.uk\/emc\/medicine\/24141. Accessed June 22 2015."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0918-3"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000033824.02722.F7"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2517-1"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000111829.46090.92"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000271504.62325.a4"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2010.16"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.12.045"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjch.12673","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjch.12673","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.12673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T06:39:56Z","timestamp":1695537596000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jch.12673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,23]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1111\/jch.12673"],"URL":"https:\/\/doi.org\/10.1111\/jch.12673","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,23]]}}}